FDAsafety guidance72% confidence
Study Data Standards Resources
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (dme) as Merck.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Diffuse Large B-Cell Lymphoma
- Sub-indication
- DME
Related signal: Zilovertamab Vedotin Shows Promise in rrDLBCL with Standard Care in Phase 2/3 Study